Key Highlights

  • Third-quarter 2026 net loss was USD 4.6 million, or USD 0.04 per share.
  • Research and development expenses were USD 2.5 million, against USD 1.3 million.
  • Cash and cash equivalents were USD 53.3 million at September 30, 2026.
  • The company initiated a Phase 1 study of EQ504 in October 2026.

Equillium (NASDAQ:EQ) reported a third-quarter 2026 net loss of USD 4.6 million, or USD 0.04 per share, against an estimate of a loss of USD 0.05 per share, in its Quarterly Report on Form 10-Q. The clinical-stage biotechnology company develops therapies for serious autoimmune and inflammatory disorders and reported no revenue. Its primary goal is to advance EQ504, a small molecule aryl hydrocarbon receptor modulator, into and through clinical development.

Quarterly Results

Research and development expenses were USD 2.5 million, against USD 1.3 million a year earlier. General and administrative expenses were USD 2.6 million, against USD 3.3 million. Total operating expenses were USD 5.0 million, against USD 4.6 million, and the loss from operations was USD 5.0 million, against USD 4.6 million.

Interest income was USD 490 thousand, against USD 235 thousand, and total other income, net, was USD 465 thousand, against USD 345 thousand. Net loss was USD 4.6 million, against USD 4.2 million, and net loss per share was USD 0.04, against USD 0.06. Weighted-average shares outstanding were 111,923,380, against 65,322,753.

For the nine months, net loss was USD 14.6 million, or USD 0.14 per share, against USD 18.6 million, or USD 0.41 per share. The filing states Research and Development expenses decreased USD 3.1 million for the nine months, which it attributes to lower employee compensation and legal costs, partly offset by higher non-cash stock-based compensation, following the wind down of clinical studies in 2025.

EQ504 and Pipeline

In October 2026, the company initiated a Phase 1 placebo-controlled proof-of-mechanism study of EQ504. The filing states topline Phase 1 proof-of-mechanism data are targeted for the second quarter of 2027 and, subject to supportive data, a placebo-controlled proof-of-concept study in moderately to severely active ulcerative colitis is targeted to start in the second half of 2027. It adds that it cannot provide assurances regarding those timeframes or that the data are favorable.

The company acquired exclusive worldwide rights to EQ504 through the Acquisition of Ariagen, Inc. in October 2024, and it initiated IND-enabling development activities for EQ504 as a potential inhaled therapy for inflammatory lung diseases. It also holds EQ302, a nonclinical-stage bispecific inhibitor of IL-15 and IL-21 formulated for oral delivery, acquired through Bioniz Therapeutics in February 2022.

Cash and Financing

As of September 30, 2026, the company had USD 53.3 million in cash and cash equivalents and an accumulated Deficit of USD 230.8 million. After quarter end, it completed an Equity Financing with gross proceeds of approximately USD 20.0 million. The filing states management believes cash at September 30, 2026, together with net proceeds from that financing, is sufficient to fund operations for at least 12 months from the date of the quarterly report.

On March 13, 2026, the company closed a private Placement in which it issued 1,179,508 shares of common stock at USD 1.854 per share and a pre-funded warrant. The filing states it has not generated product sales, and that it would need to raise additional Capital to implement its plans. It lists among its risks a past failure to maintain compliance with Nasdaq Capital Market listing requirements.